Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Net Cash Flow data on file, last reported at $182.3 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $182.3 million, up 256.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $330.7 million (up 15876.67% YoY), and the FY2025 annual result was $31.9 million, down 33.35% from the prior year.
• Net Cash Flow improved to $182.3 million in Q1 2026 per DNLI's latest filing, from $114.4 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $182.3 million in Q1 2026 and troughed at -$188.5 million in Q1 2022.
• A 5-year average of $5.6 million and a median of $16.0 million in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 503.37% in 2024, then plunged 414.87% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $99.4 million in 2022, then plunged by 121.03% to -$20.9 million in 2023, then surged by 503.37% to $84.3 million in 2024, then jumped by 35.62% to $114.4 million in 2025, then soared by 59.4% to $182.3 million in 2026.
• Business Quant data shows DNLI's Net Cash Flow at $182.3 million in Q1 2026, $114.4 million in Q4 2025, and -$50.2 million in Q3 2025.